Disc Medicine initial Phase 1b/2 data: DISC-0974 shows dose-dependent hepcidin reduction and Hb improvement in MF anemia

Disc Medicine, Inc.

DISC-0974 reduced serum hepcidin >75% and increased serum iron >75% at 28 mg dose.
57% (4/7) of evaluable non-transfusion-dependent patients achieved ≥1.5 g/dL hemoglobin increase.
One of two transfusion-dependent patients achieved transfusion independence per Gale Criteria.
Hematologic activity observed regardless of concomitant JAK inhibitor use; drug generally well-tolerated.
Data presented at ASH 2023; dose escalation ongoing with 11 evaluable subjects from three dose levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.